Penumbra (PEN) Q2 Revenue Jumps 13%

Penumbra (NYSE:PEN), a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP revenue and $0.86 in non-GAAP earnings per share, Revenue exceeded analyst expectations. Revenue (GAAP) exceeded the consensus estimate by $11.7 million. These numbers were powered by double-digit growth in its U.S. thrombectomy business and improved profitability. Despite continued contraction in international sales, especially in China, management characterized the quarter as a strong one and increased full-year revenue guidance. Margin expansion was another highlight as one-time charges from the prior year rolled off and the mix shifted to higher-value products. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Penumbra specializes in producing medical devices that treat vascular conditions, particularly by providing tools for removing clots from blood vessels (thrombectomy) and for stopping unwanted blood flow (embolization). Its core business revolves around its thrombectomy and embolization systems, which are used by physicians to restore blood flow or control bleeding in critical situations like stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and other vascular blockages.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool